Edwards’ Sapien 3 Ultra TAVR valve gains FDA approval

The Sapien 3 Ultra heart valve has received FDA approval for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are considered to be at intermediate or high risk of open-heart surgery, device manufacturer Edwards Lifesciences announced on Dec. 28.

"The advanced Sapien 3 Ultra system features enhancements on the valve and a new delivery system to address the needs of both patients and clinicians, building on our best-in-class performance of Sapien 3 to further advance and improve patient care," Larry L. Wood, Edwards' corporate vice president of transcatheter heart valves, said in a press release. "We look forward to introducing the Sapien 3 Ultra system to U.S. patients."

The device previously received CE mark approval in November. Specifically, the new design includes a heightened outer skirt designed to prevent paravalvular leak and a 14-French expandable sheath, according to Edwards. The valve comes in 20, 23 and 26 millimeter sizes.

""

Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."